Incidence (in %) and OR of primary and secondary end-points in the study cohort, broken down by use of red blood cell units
| Parameters . | RBC− group (n = 1478) . | RBC+ group (n = 1528) . | Unadjusted OR (95% CI) . | PS-adjusted ORa (95% CI) . | P value . |
|---|---|---|---|---|---|
| Primary end-point | |||||
| Thirty-day mortality | 0.3% | 0.2% | 0.73 (0.16;3.27) | 0.29 (0.06;1.50) | 0.140 |
| Secondary end-points | |||||
| Low cardiac output syndrome | 0.6% | 1.2% | 2.07 (0.94;4.59) | 1.55 (0.64;3.79) | 0.334 |
| Stroke | 0.6% | 0.6% | 0.98 (0.39;2.46) | 0.74 (0.24;2.24) | 0.588 |
| Haemofiltration | 0.1% | 0.2% | 2.93 (0.30;28.20) | 5.20 (0.45;60.29) | 0.187 |
| Wound infection | 0.3% | 0.2% | 0.73 (0.16;3.27) | 0.76 (0.14;4.12) | 0.745 |
| Prolonged ICU stay (>48 h) | 9.2% | 11.9% | 1.33 (1.05;1.68) | 1.49 (1.14;1.95) | 0.004 |
| Prolonged mechanical ventilatory support (>24 h) | 0.9% | 1.4% | 1.56 (0.78;3.14) | 2.22 (0.99;4.96) | 0.052 |
| Parameters . | RBC− group (n = 1478) . | RBC+ group (n = 1528) . | Unadjusted OR (95% CI) . | PS-adjusted ORa (95% CI) . | P value . |
|---|---|---|---|---|---|
| Primary end-point | |||||
| Thirty-day mortality | 0.3% | 0.2% | 0.73 (0.16;3.27) | 0.29 (0.06;1.50) | 0.140 |
| Secondary end-points | |||||
| Low cardiac output syndrome | 0.6% | 1.2% | 2.07 (0.94;4.59) | 1.55 (0.64;3.79) | 0.334 |
| Stroke | 0.6% | 0.6% | 0.98 (0.39;2.46) | 0.74 (0.24;2.24) | 0.588 |
| Haemofiltration | 0.1% | 0.2% | 2.93 (0.30;28.20) | 5.20 (0.45;60.29) | 0.187 |
| Wound infection | 0.3% | 0.2% | 0.73 (0.16;3.27) | 0.76 (0.14;4.12) | 0.745 |
| Prolonged ICU stay (>48 h) | 9.2% | 11.9% | 1.33 (1.05;1.68) | 1.49 (1.14;1.95) | 0.004 |
| Prolonged mechanical ventilatory support (>24 h) | 0.9% | 1.4% | 1.56 (0.78;3.14) | 2.22 (0.99;4.96) | 0.052 |
ICU: intensive care unit; OR: odds ratio; PS: propensity score; RBC: red blood cells.
aAdjusted for propensity score.
Incidence (in %) and OR of primary and secondary end-points in the study cohort, broken down by use of red blood cell units
| Parameters . | RBC− group (n = 1478) . | RBC+ group (n = 1528) . | Unadjusted OR (95% CI) . | PS-adjusted ORa (95% CI) . | P value . |
|---|---|---|---|---|---|
| Primary end-point | |||||
| Thirty-day mortality | 0.3% | 0.2% | 0.73 (0.16;3.27) | 0.29 (0.06;1.50) | 0.140 |
| Secondary end-points | |||||
| Low cardiac output syndrome | 0.6% | 1.2% | 2.07 (0.94;4.59) | 1.55 (0.64;3.79) | 0.334 |
| Stroke | 0.6% | 0.6% | 0.98 (0.39;2.46) | 0.74 (0.24;2.24) | 0.588 |
| Haemofiltration | 0.1% | 0.2% | 2.93 (0.30;28.20) | 5.20 (0.45;60.29) | 0.187 |
| Wound infection | 0.3% | 0.2% | 0.73 (0.16;3.27) | 0.76 (0.14;4.12) | 0.745 |
| Prolonged ICU stay (>48 h) | 9.2% | 11.9% | 1.33 (1.05;1.68) | 1.49 (1.14;1.95) | 0.004 |
| Prolonged mechanical ventilatory support (>24 h) | 0.9% | 1.4% | 1.56 (0.78;3.14) | 2.22 (0.99;4.96) | 0.052 |
| Parameters . | RBC− group (n = 1478) . | RBC+ group (n = 1528) . | Unadjusted OR (95% CI) . | PS-adjusted ORa (95% CI) . | P value . |
|---|---|---|---|---|---|
| Primary end-point | |||||
| Thirty-day mortality | 0.3% | 0.2% | 0.73 (0.16;3.27) | 0.29 (0.06;1.50) | 0.140 |
| Secondary end-points | |||||
| Low cardiac output syndrome | 0.6% | 1.2% | 2.07 (0.94;4.59) | 1.55 (0.64;3.79) | 0.334 |
| Stroke | 0.6% | 0.6% | 0.98 (0.39;2.46) | 0.74 (0.24;2.24) | 0.588 |
| Haemofiltration | 0.1% | 0.2% | 2.93 (0.30;28.20) | 5.20 (0.45;60.29) | 0.187 |
| Wound infection | 0.3% | 0.2% | 0.73 (0.16;3.27) | 0.76 (0.14;4.12) | 0.745 |
| Prolonged ICU stay (>48 h) | 9.2% | 11.9% | 1.33 (1.05;1.68) | 1.49 (1.14;1.95) | 0.004 |
| Prolonged mechanical ventilatory support (>24 h) | 0.9% | 1.4% | 1.56 (0.78;3.14) | 2.22 (0.99;4.96) | 0.052 |
ICU: intensive care unit; OR: odds ratio; PS: propensity score; RBC: red blood cells.
aAdjusted for propensity score.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
